Stories from Darmstadt, Germany

28.05.2020 – 10:00

Merck KGaA
Merck and Twitch Join Forces on World Multiple Sclerosis Day to Connect People Living With MS

Darmstadt, Germany (ots/PRNewswire) - - Merck and Twitch collaborate on World MS Day to increase understanding of the impact of multiple sclerosis (MS) - Livestream event with Twitch influencers on May 30 will raise awareness and money for the MS International Federation and help connect people affected by the disease, in line with official World MS Day theme MS ...

more
14.05.2020 – 00:23

Merck KGaA
Breakthrough Innovation in Cancer Care From Merck Pipeline to Be Presented at ASCO 2020

Darmstadt, Germany (ots/PRNewswire) - - Results from two studies of BAVENCIO® to be featured in ASCO press briefing - Primary efficacy, biomarker and HRQoL analyses for tepotinib?, the first MET inhibitor to have received a regulatory approval for NSCLC with MET gene alterations - Two-year follow-up for first-in-class bifunctional immunotherapy bintrafusp alfa? ...

more
30.04.2020 – 14:00

Merck KGaA
Data From Merck at ASCO 2020 to Showcase Significant Clinical Advances in Cancer Care

Darmstadt, Germany and New York (ots/PRNewswire) - - Not intended for US-, Canada- or UK-based media - ASCO Abstract # BAVENCIO® (avelumab): LBA1, 5061; Bintrafusp alfa (bifunctional fusion protein): 9558; Tepotinib (MET kinase inhibitor): 9556, 9575. - Late-breaking presentation of Phase III JAVELIN Bladder 100 data for BAVENCIO® showing overall survival benefit in ...

more
02.03.2020 – 08:01

Merck KGaA
ERBITUX® Approved for First-line Use in China in Patients With Recurrent and/or Metastatic Squamous Cell Carcinoma of the Head and Neck (R/M SCCHN)

Darmstadt, Germany (ots/PRNewswire) - Approval is for ERBITUX® in combination with platinum-based therapy with fluorouracil for the first-line treatment of R/M SCCHN Pivotal Phase III study shows significant improvements with ERBITUX® in combination with platinum-based therapy with fluorouracil in response rate, ...

more
20.11.2019 – 08:01

Merck KGaA
Merck Announces Orphan Drug Designation for Investigational Therapy Tepotinib in Patients with NSCLC Harboring MET Gene Alterations

Darmstadt, Germany (ots/PRNewswire) - - Japanese Ministry of Health, Labour and Welfare grants orphan drug designation for diseases that affect fewer than 50,000 patients in Japan, and for which significant unmet medical need exists - MET exon 14 (METex14) skipping alterations and MET amplifications are present in ...

more
28.10.2019 – 19:00

Merck KGaA
European Commission Approves BAVENCIO® (avelumab) Plus Axitinib Combination for First-Line Treatment of Patients With Advanced Renal Cell Carcinoma

Darmstadt, Germany, and New York (ots/PRNewswire) - Not intended for US, Canada and UK-based media -- EU approval based on JAVELIN Renal 101 trial results demonstrating significant improvement in progression-free survival with BAVENCIO in combination with axitinib compared with sunitinib -- Combination regimen ...

more
27.09.2019 – 08:01

Merck KGaA
Abstracts highlight data on BAVENCIO as a monotherapy and in combination in multiple advanced cancers

Darmstadt, Germany, and New York (ots/PRNewswire) - Not intended for US, Canada and UK-based media Merck and Pfizer Inc. (NYSE: PFE) today announced the presentation of multiple analyses from the JAVELIN clinical development program assessing BAVENCIO® (avelumab) alone or as part of combination regimens for the ...

more
23.09.2019 – 08:01

Merck KGaA
New Data at ESMO 2019 for Merck Highlight Focused Clinical Development and Commitment to Patient Care

Darmstadt, Germany (ots/PRNewswire) - Not intended for distribution in the USA, Canada or the UK Key ESMO Abstracts # BAVENCIO® (avelumab): 1451; 3152; 4174; 4256; 4823; 5113, ERBITUX® (cetuximab): 1212, 2589, 4455, Tepotinib (MET kinase inhibitor): 3930; 5373; 5455, M6620 (ATR inhibitor): 1547, Combinations: ...

more
20.09.2019 – 14:10

Merck KGaA
CHMP Adopts Positive Opinion for BAVENCIO® (avelumab) Plus Axitinib for First-Line Treatment of Patients with Advanced Renal Cell Carcinoma

Darmstadt, Germany and New York, Us (ots/PRNewswire) - Not intended for US, Canada and UK-based media - Opinion based on Phase III data showing combination lowered risk of disease progression or death by 31% and improved objective response rate compared with sunitinib1 - Decision by the European Commission ...

more
11.09.2019 – 08:30

Merck KGaA
Merck Announces FDA Breakthrough Therapy Designation for Investigational Therapy Tepotinib in Patients with Metastatic NSCLC with METex14 Skipping Alterations

Darmstadt, Germany (ots/PRNewswire) - - Investigational oral MET inhibitor has previously received SAKIGAKE 'fast-track' regulatory designation in Japan - MET exon 14 skipping alterations and MET amplifications are present in 3-5% of non-small cell lung cancer patients and correlate with poor prognosis - The ...

more
09.09.2019 – 14:00

Merck KGaA
Updated Results for Investigational Therapy Tepotinib Presented at WCLC 2019

Darmstadt, Germany (ots/PRNewswire) - - Results include progression-free survival and overall survival data from Phase Ib/II INSIGHT study - Phase II INSIGHT 2 study now open for enrollment for patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) mutation and select MET dysregulations The ...

more
24.06.2019 – 14:00

Merck KGaA
Merck to Showcase New Data Across MS Portfolio at EAN 2019

Darmstadt, Germany (ots/PRNewswire) - Not intended for UK or U.S. based media - Company to present 16 abstracts on MAVENCLAD® (cladribine tablets), Rebif® (interferon beta-1a) and investigational evobrutinib at the 5th Congress of the European Academy of Neurology - Presentations include new data on the long-term efficacy and safety of MAVENCLAD®, new safety data for Rebif® and the 48-week analysis from the Phase 2 ...

more
03.06.2019 – 19:28

Merck KGaA
Merck Presents Updated Results for Investigational Therapy Tepotinib Demonstrating Durable Clinical Response in Patients with Advanced NSCLC with METex14 Skipping Mutations

Darmstadt, Germany (ots/PRNewswire) - ASCO Abstract # Tepotinib (MET kinase inhibitor): 9005 Not intended for UK- , Canada- or US-based media - Alterations of the MET signaling pathway are present in 3-5% of non-small cell lung cancer patients and correlate with poor prognosis - New interim data from Phase II VISION ...

more
30.05.2019 – 10:01

Merck KGaA
Merck Pioneers New Efforts to See MS From the Inside Out

Darmstadt, Germany (ots/PRNewswire) - Not intended for media in the UK and the U.S. - Company launches global art campaign for people with MS to express their invisible symptoms and the unseen impact of the disease - Thought-provoking campaign coincides with the launch of MSonyourterms.com (http://www.msonmyterms.com/), a resource for patients, carers, and the public to understand MS from the Inside Out - Merck to donate ...

more
16.05.2019 – 00:18

Merck KGaA
Merck Data at ASCO 2019 Showcase Multiple Innovative Molecules with Potential to Impact Unmet Needs in Cancer Care

Darmstadt, Germany (ots/PRNewswire) - Not intended for UK- , Canada- or US-based media ASCO Abstract # Bintrafusp alfa (bifunctional fusion protein): TPS9114; Tepotinib (MET kinase inhibitor): 9005; Discovery: 2567; ERBITUX® (cetuximab): 3580; BAVENCIO® (avelumab): 9569; 101; 4552; 4072 - New biomarker analyses ...

more
10.05.2019 – 19:46

Merck KGaA
Positive Phase II Data Further Highlights Clinical Proof of Concept for Evobrutinib, First Oral Bruton´s Tyrosine Kinase (BTK) Inhibitor to Report Positive Phase II Clinical Results in MS

Darmstadt, Germany (ots/PRNewswire) - Not intended for U.S. media - 48-week results provide additional evidence of relapse reduction for investigational evobrutinib - Evobrutinib demonstrated rapid lesion reductions on MRI at week 12 that were maintained through week 48, with no new safety signals identified over 52 ...

more
30.04.2019 – 14:05

Merck KGaA
Merck to Present New Data on Mavenclad®, Rebif® and the Investigational Therapy Evobrutinib at the AAN Annual Meeting 2019

Darmstadt, Germany (ots/PRNewswire) - Not intended for U.S. or U.K. based media - 20 abstracts will be presented during the AAN Annual Meeting 2019 to demonstrate Merck's commitment and clinical development program in multiple sclerosis Merck, a leading science and technology company, today announced that data from ...

more
30.03.2019 – 01:02

Merck KGaA
FDA Approves MAVENCLAD® (Cladribine) Tablets as First and Only Short-Course Oral Treatment for Relapsing-Remitting and Active Secondary Progressive Multiple Sclerosis

Darmstadt, Germany (ots/PRNewswire) - - MAVENCLAD is the first oral MS treatment to provide two years of proven efficacy with a maximum of 20 days of treatment - MAVENCLAD's unique mechanism may provide an important new option for patients with ongoing active disease - MAVENCLAD demonstrated significant efficacy ...

more
25.03.2019 – 12:04

Merck KGaA
MAVENCLAD® (Cladribine Tablets) Approved As The First Short-Course Oral Treatment for Relapsing Remitting Multiple Sclerosis in Switzerland

Darmstadt, Germany (ots/PRNewswire) - - MAVENCLAD® is now approved in 52 countries worldwide - Approval brings forward new treatment option with a novel mechanism for highly active relapsing multiple sclerosis in Switzerland - Approval based on extensive clinical development program capturing more than 10,000 ...

more
19.03.2019 – 23:47

Merck KGaA
Merck and Pfizer Announce Discontinuation of Phase III JAVELIN Ovarian PARP 100 Trial in Previously Untreated Advanced Ovarian Cancer

Darmstadt, Germany and New York (ots/PRNewswire) - Not intended for US, Canada and UK-based media Merck and Pfizer Inc. (NYSE: PFE) today announced the discontinuation of the ongoing Phase III JAVELIN Ovarian PARP 100 study evaluating the efficacy and safety of avelumab in combination with chemotherapy followed by ...

more
14.03.2019 – 14:02

Merck KGaA
Merck Announces Collaboration With Iktos for Generative Artificial Intelligence (AI) Technology

Darmstadt, Germany (ots/PRNewswire) - Not intended for US, Canada and UK-based media - Collaboration agreement enables Merck access to Iktos AI technology across three drug discovery projects - Generative modelling AI technology enables rapid and cost-effective design of novel drugs - Agreement is part of Merck's R&D strategy to advance drug discovery with strategic ...

more
16.02.2019 – 23:10

Merck KGaA
Pivotal Phase III Data for BAVENCIO® (avelumab) Plus INLYTA® (axitinib) in Advanced Renal Cell Carcinoma Published in the New England Journal of Medicine

Darmstadt, Germany and New York (ots/PRNewswire) - Not intended for US, Canada and UK-based media - JAVELIN Renal 101 shows significant improvement in progression-free survival with a hazard ratio of 0.69 in patients regardless of PD-L1 expression - US FDA has granted Priority Review to BAVENCIO plus INLYTA for ...

more
11.02.2019 – 23:55

Merck KGaA
FDA Accepts sBLA and Grants Priority Review for BAVENCIO® (avelumab) Plus INLYTA® (axitinib) for the Treatment of Advanced Renal Cell Carcinoma

Darmstadt, Germany and New York (ots/PRNewswire) - Not intended for US, Canada and UK-based media Merck and Pfizer Inc. (NYSE: PFE) today announced that the US Food and Drug Administration (FDA) has accepted for Priority Review the supplemental Biologics License Application (sBLA) for BAVENCIO® (avelumab) in ...

more
06.02.2019 – 15:01

Merck KGaA
Merck to Expand US Biopharmaceutical R&D Facility to Advance Innovative Clinical Pipeline

Darmstadt, Germany (ots/PRNewswire) - Not intended for US, Canada or UK-based media Merck to Expand US Biopharmaceutical R&D Facility to Advance Innovative Clinical Pipeline - Merck investing $70 million in U.S. Research & Development Hub - Expansion of R&D footprint to accelerate science and innovation in Oncology, ...

more
05.02.2019 – 13:19

Merck KGaA
Merck and GSK Announce Global Alliance to Jointly Develop and Commercialize M7824, a Novel Immunotherapy with Potential in Multiple Difficult-to-Treat Cancers

Darmstadt, Germany (ots/PRNewswire) - Not intended for US, Canada or UK-based media - Eight high priority immuno-oncology clinical development studies ongoing or expected to commence in 2019, including studies in non-small cell lung and biliary tract cancers - Merck will receive an upfront payment of EUR300 million ...

more
24.01.2019 – 14:01

Merck KGaA
Merck Grants Exclusive License to Vertex for Two DNA Damage Response Inhibitors

Darmstadt, Germany (ots/PRNewswire) - Not intended for UK- or US-based media - Exclusive license grants Vertex one clinical and one pre-clinical DNA-PK inhibitor for use in gene-editing applications in six specific genetic disease areas - Merck retains the rights to both compounds in all other disease areas, including oncology - Merck retains the rights to utilize and ...

more
21.12.2018 – 20:02

Merck KGaA
Merck and Pfizer Provide Update on JAVELIN Ovarian 100 Trial of Avelumab in Previously Untreated Advanced Ovarian Cancer

Darmstadt, Germany and New York (ots/PRNewswire) - Not intended for US, Canada and UK-based media Merck and Pfizer Inc. (NYSE: PFE) today announced that data from a planned interim analysis of the Phase III JAVELIN Ovarian 100 study of avelumab* did not support the study's initial hypothesis, and therefore the ...

more

12345Next